Design and validation of a clinical whole genome sequencing-based assay for patient screening in a large healthcare system

TL;DR

This paper describes the development and validation of a whole genome sequencing method for clinical screening of actionable genomic conditions in a large healthcare system.

Contribution

The paper introduces a validated clinical whole genome sequencing-based assay for scalable patient screening.

Findings

The WGS-based lab developed procedure demonstrated excellent sensitivity, specificity, and accuracy.

Over 2,000 patients were sequenced using the deployed LDP as part of a broader clinical implementation study.

The findings support the viability of WGS for broad clinical screening.

Abstract

Population genetic screening is rapidly emerging as a key methodology in the clinical laboratory for detecting actionable genomic conditions in asymptomatic patients. While current clinical methods are largely focused on targeted gene panels, the increasing efficiency of next-generation sequencing (NGS) platforms permits the use of whole genome sequencing (WGS) for routine clinical applications. The key advantage of WGS is that the complete genome produced by a single sequencing event can form the basis for a patient’s genomic health care record for reanalysis throughout a patient’s lifetime.

We developed a scalable clinical WGS-based lab developed procedure (LDP) for heritable disease gene testing and pharmacogenomics (PGx). We performed extensive validation across a range of blood, saliva, and reference specimens.

The clinical deliverable for the WGS LDP was 78 genes associated with actionable genomic conditions and 4 PGx genes. The validation cohort consisted of samples from 188 study participants that were orthogonally sequenced at commercial reference laboratories and additional reference materials. The WGS LDP demonstrated excellent sensitivity, specificity, and accuracy.

The deployed LDP was then used to sequence over 2,000 patients as part of a broader clinical implementation study (“Geno4ME”). Our findings support WGS as a viable method for broad clinical screening.

Figures